December 04, 2017
2 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: No increased safety risk associated with increasing tocilizumab exposure
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN DIEGO — At the American College of Rheumatology Annual Meeting, Shalini Mohan, MD, discussed a study that provided an update of the safety of tocilizumab treatment in patients with rheumatoid arthritis, using data from multiple clinical trials and the global tocilizumab post-marketing safety database. According to Mohan, the results were consistent with previous safety reports, and indicate there is no evidence of increased safety risk with increasing exposure to tocilizumab.